This mutual exclusivity between ESR1 and RTK/MAPK pathway mutations is consistent with previous observations in HR + /HER2- MBC11,12,16.To our knowledge, the presence of these oncogenic mutations had not been linked to the PAM50 molecular subtype of a tumor until very recently in the AURORA study29. This evidence concerns the gene ESR1 and neoplasm.